Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's fine, but there's a perception here that Leo and others sacrificed for the good of the company... That's not accurate as the reason for cost cutting was because of failed policy. Meaning, the hiring and firing of George Evans which cost them a million bucks. The patent shares handed over to Aruda was another blemish. It's easy to lay all-the-blame this year on Mako/Rosen, but there's other issues as well. I'm hoping Leo changes his tactics as CEO and issues PRS ONLY when there is substantial news. No more PRs on President Obama, short sellers, Mako, frozen drugs and we're about to do this or that in 3 years... When the judge dismisses the Rosen case, have a short PR and move on.
sox, There has to be fair balance when judging the past with this company. They ousted the CEO George Evans back in 2011 and settled with a million dollar buyout. Also, Leo made 2 huge mistakes this year with the up-listing process. I also doubt Leo/Menon had no rewards of any kind during those years... Meaning, stock options and so on... There's many reasons why the price is at 1.40... Hopefully, Leo has learned from his mistakes and stops the childish PRs that set this company back. Blaming shorts and Mako continually is unprofessional when his mistake "not being prepared" to up-list was his fault.
http://www.firstwordpharma.com/node/834388#axzz3uvnHkz00
Last Hit-Piece by Mako... Ocata price target 0, office appears empty!!! Since then, Ocata was bought out for 8.50. Phillip Kim, huge mistake for using Mako as "key evidence" for your lawsuit. Even if they dig up more dirt on CTIX, the judge will have to stand on the evidence prior to the lawsuit. Which was 100 percent drawn from the SA hit-piece. If Rosen waited a few weeks they could have added more ammunition to the case, but filing a suit 30 minutes after the SA article limits Rosen's arguments.
http://seekingalpha.com/article/3528856-ocata-dilution-imminent-sec-investigation-potentially-underway-office-appears-empty-price-target-0_00
http://www.xconomy.com/boston/2015/11/10/with-379m-deal-for-ocata-astellas-buys-stem-cells-for-eye-diseases/
The main evidence in this case (Mako Research) has been idle on SA since September 23. Seems strange considering they released (6 hit pieces) within 5 weeks. There's nothing new that can be added to this case, so it makes no sense for the judge to keep this going. I wonder if the judge was able to contact anyone related to Mako Research? All Sullivan has to do is discredit Mako (key witness) which is easy to do... 2 factors going for Leo is the Ocata buyout, who were attacked twice by Mako and Rosen issuing the lawsuit one hour after the Mako hit. Add, the disappearance by Mako since, so how could any judge side with Rosen? There's also no point in a settlement by CTIX as that would cast doubt to their credibility. Rosen is playing with fire as the damages caused by Mako/Rosen are in the millions (lost market cap). I believe, Rosen thought CTIX was an easy target... Boy were they wrong and if CTIX has a successful defense, Rosen stands to lose a ton. Meaning, financially and name recognition. There's no doubt, Sullivan will "counter sue" for lost market cap and other damages as well. Rosen has liability insurance just for these situations...
The demise of stock price is not just contributed to shorts/Mako. Leo made a HUGE error by not being prepared to up-list when the PPS was firmly above 2 for 5 straight months. Then, he announces to-the-world when he files for approval? 2 major mistakes!!!
1. Not being prepared to up-list (BOD's in place)
2. Making an announcement for application. (short ammunition)
Buyers left for the holidays. Tax sellers and shorts controlling the action now. 7 press releases since November 1st with a SH meeting... The stock is down 25 percent since last-week... The biggest blunder (not up-listing) counters all the good that was achieved in 2015...
There's a 30 day wash rule where you can't buy back and still deduct the loss. Those rules were put in place to prevent such strategy. However, in an IRA you can sell and buy back with no restrictions.
http://www.investopedia.com/terms/w/washsalerule.asp
Thanks Matagordaville, Not keeping quiet (up-listing process) cost the shareholders dearly. Tipped the shorts, made Leo look foolish and enhanced the Mako attack.
I asked Leo What was one or two things as a lesson learned in 2015?
He responded in summary to remain quiet concerning uplist.
Will 1.50 hold? That's about all we have to hope for after a SH meeting. Mako and crew continue to own this equity.
Why does Leo need to partner? Everything is great from yesterday's PR. They have 30 million-in-the-bank and a solid stock price to support dilution.
I'm not short or a flipper. Just a shareholder down 50 percent like everyone else.
Hopefully, they don't have the stock price on display... I feel bad for the shareholders who continue to believe, while the shorts continue to prosper.
More reasons to do a RS and rid yourself of this rigged game. Like I said yesterday, everything is great but the most important thing... The stock price continues to languish in hell.
Shorts/Mako still manipulating even when the meeting starts. All sells right before 10PM, what a freggen joke of an investment. Hopefully, Leo gets asked about the PPS stuck in regression mode.
Leo can connect the dots all he wants, the reality is a stock that's not drawing any interest because of the price and the market it trades on. The stock was down 35 percent YTD before the Mako attack. Mako just put icing on-the-cake.
Another PR with a negative reaction. That's about 6 PR's "the past 3 weeks" with the PPS continuing to slide. How can Leo sit there tomorrow and ask for support, when there's no credibility to the market they trade on?
Hasn't been a great year for shareholders Leo. Looks great on paper how everything is progressing, but the reality is a dying PPS that's easily manipulated. If the PPS cannot rebound in early 2016, the prospects of a RS will increase to get off the pinks. Should have been done last-spring...
Phillip Kim's followings on SA appear to be mostly tied to shorting. Interesting that a blood sucking lawyer would be tied to these folks? I hope Sullivan targets Kim directly for possible inside trading!!! There's no way Rosen would release legal action an hour after Mako's hit without some knowledge beforehand...
http://seekingalpha.com/user/705988/following
Mako in hiding... No articles since September 23. More ammunition for CTIX/Sullivan as they can point out the 6 articles (all hit pieces) occurred within 5 weeks and none since? Also, 2 of the "hit piece" articles (Ocata) were on a company that's since been bought out for a hefty premium. Since Mako is the main evidence in the CTIX case, how could any judge uphold a guilty verdict?
http://seekingalpha.com/author/mako-research/articles
Top Medical Device Companies. The top 4 are US based, Bayer is 30th and has a prior connection with Dr Menon, but they're not US.
http://www.mpo-mag.com/issues/2015-07-01/view_features/top-30-global-medical-device-companies
TOP?MEDICAL?DEVICE MANUFACTURERS
1. Johnson & Johnson $27.50B
2. GE Healthcare $18.29B
3. Medtronic $17.00B
4. Baxter International $16.67B
5. Siemens Healthcare $15.77B
6. Philips Healthcare $11.17B
7. Cardinal Health $11.00B
8. Covidien $10.66B
9. Abbott Labs $10.11B
10. Stryker $9.66B
11. Danaher $9.38B
12. Becton Dickinson $8.45B
13. Boston Scientific $7.38B
14. Essilor $6.89B
15. Alcon $6.62B
16. B. Braun $6.59B
17. Fresenius $5.95B
18. St. Jude Medical $5.62B
19. 3M Healthcare $5.57B
20. Olympus Medical $4.79B
21. Zimmer $4.67B
22. Smith & Nephew $4.62B
23. Hospira $4.50B
24. Terumo $4.09B
25. CareFusion $3.84B
26. Getinge Group $3.42B
27. C.R. Bard $3.32B
28. Biomet $3.20B
29. Varian Medical $3.00B
30. Bayer $2.87B
- See more at: http://www.mpo-mag.com/issues/2015-07-01/view_features/top-30-global-medical-device-companies#sthash.b1bBt6IX.dpuf
Must Read, Clearance for Devices with Antibiotics... Exactly why a device maker would want to partner with CTIX...The Regulatory Challenges of Obtaining 510(k) Clearance for Devices with Antibiotics...
http://www.mddionline.com/blog/devicetalk/regulatory-challenges-obtaining-510k-clearance-devices-antibiotics-08-06-15
Conclusion
Companies seeking to market new devices containing antibiotics in today’s regulatory environment should take the following steps:
Be careful to avoid labeling or technological characteristics that can lead FDA to question the PMOA.
Match the indications and drug formulation, concentration, anatomic location, and release profile as closely as possible to a predicate device, to increase the chances of being regulated via the 510(k) pathway.
Be aware that, regardless of the regulatory path, FDA may insist data be presented that demonstrate reduction in infection rates or some clinical benefit other than prevention of device colonization.
Last half-hour sell-off to unchanged or down a penny. Been that pattern all-week. Just like clock-work... a few traders have total control over this stock.
Hopefully, the average age of CTIX investors are below 55. The time it takes to get something accomplished takes 10 years on average here. Even a paper submitted will be 2 years... LOL
Where is the paper? Like everything else with CTIX, we'll see it in a year.
Hopefully, Leo gets asked about the terrible PPS and if he has any solutions other than saying how great everything is. Eventually, the hype "if not already" starts to backfire if there seems to be "no strategy" for changes. This means all options on-the-table including a reverse split. Was staying on the pink-sheets any better? For someone (Leo) who keeps complaining about short traders, well, who's fault is that? Leo made the decision to stay on the pinks and has zero influence for a higher PPS.
Karin, you posted that yesterday... It's old news, this company needs to do something major to get interest in this stock. Going to be much harder raising funds with a stock below 2 trading on-the-pinks.
How do you know the naked shorts have increased? The daily stats are not a true indicator. The biggest drag on the stock is tax selling now.
Short positions decreased again. From 1,071,059 million to 1,035,660 in 2 weeks. Trend has been decreasing.
http://otce.finra.org/ESI/Archives
Cellceutix Corporation Common|CTIX|u|1071059|1035660|35399|3.42|245924|4.36
Hopefully, Leo makes only one announcement on any up-listing!!! When they have approval. Too much info shared has backfired in many ways.
Leo had plenty of time to up-list above 2, but didn't have the BOD's in place. Why tip-your hand at all (filing PR), then can't deliver. Blaming shorts for not up-listing when he (Leo) wasn't prepared was a huge mistake. Cost the shareholders greatly and probably enhanced the Mako attack...
Also, most companies do not have SH meetings in mid December. I believe Leo will have a surprise as well. When he circled that date, PPS strategy came to mind no doubt...
Interesting that Leo chose December 15th for the meeting. Right when tax selling should be subsiding and the Rosen effect beginning to dissolve.
Pre-SH Meeting Rally... I'm expecting big news the day of the event. K phase 1 results would be nice.
Short positions are less than 2 percent of float. A rally will have to come by news that draws new buyers. Failure to up-list last winter/spring continues to haunt this stock.
Phteven C, How can you explain the move to almost 5 last year? Same market, same players involved and so on... This stock is stuck under 2 for many reasons. Tax selling, dilution, shorts and the Rosen effect. Leo needs release the (Phase 1) K results ASAP. Until then, the same trading pattern will continue.
Short positions down 25 percent since January.
http://otce.finra.org/ESI/Archives
11/13/15 short totals: 1,052,676 million
1/15/15 1,319,833 million
The shorts are not growing. They've decreased the past few months. The daily short figures by FINRA are bogus. See below...
The daily short interest report from FINRA is as widely misinterpreted as any report ever put out. Yet, once a few basics are understood, it becomes very logical. The huge short volume seen in the daily reports are almost instantaneously covered; within a few milliseconds or a few hours at worst. The best explanation of this report, that I've ever seen, was posted by "Dave Patch" of "Investigatethesec.com."
Posted by: patchman Date: Wednesday, March 03, 2010 6:31:31 PM
In reply to: fourkids_9pets who wrote msg# 648 Post # of 951
Short Sale Volume Reporting’s are deceiving.
I spoke to FINRA today and found out some very interesting things that until now I did not fully understand. I knew there was something wrong with this transparency of information but was not 100% sure what it was. I think I have my answer and it was enlightening.
I was first directed to the Notice to Members memo dated 9/29/2009
www.finra.org/Industry/Regulation/Notices/2009/P120045
The individual I spoke with wanted to make clear that to maintain proper trade volume reporting accuracy, a trade with multiple legs in the trade would only be reported once in the volume reports. The example given would be.
Investor A is long 100 shares and wants to sell. They enter the order through their broker that is routed to a market maker. That market maker will go out and sell the stock into the market before they have bought the stock from you/your broker to close out their account. They do not take possession first as there is no guarantee they can sell the order into the market. By this Notice, the actual sale INTO the market is a short sale because the market maker sold the stock into the market BEFORE they had purchased the stock from you. It is a technicality since they know there position will be closed out minutes later when they go in and buy your shares. To avoid doubling up on trade volume and distorting the picture, only the sale into the market (consolidated tape) is recorded and not the second leg which was the sale transaction between seller and market maker.
So, this is why the short sale volume is high but also why the FTD’s and bi-Monthly short interest reports are not showing any indications of this volume. The short isn’t really a short it is the execution of a long sale by a market maker. The key language in the FINRA notice is this:
Quote:
--------------------------------------------------------------------------------
The Daily Short Sale Volume File will provide daily access to the aggregate volume of short sales in NMS Stocks and OTC Equity Securities reported to a consolidated tape and traded over-the-counter during regular trading hours on each trading day.
Tax selling and dilution are not helping either. Need to get the Rosen case behind us and hopefully up-list after. Press releases are great, but the real mover will be phase results. Leo keeps mentioning phase 2 start for K, how about releasing the phase 1 figures? I think he's waiting until the meeting... Just my guess...
Pink sheet trading at it's best. Market makers and shorts controlling the action. Failure to up-list continues to haunt this stock. Need trial results to move this forward.
Notice an increase of news as the Rosen crash-course nears. K results (Phase 1) could be the next ammo fired at Rosen...